The North America Bronchodilators Market would witness market growth of 3.0% CAGR during the forecast period (2022-2028).
Bronchodilators are indicated for patients with lower than optimal airflow through the lungs. The central pillar of the treatment is beta-2 agonists, which target the smooth muscles of the lung’s bronchioles. Numerous respiratory conditions may need bronchodilators, including asthma and chronic obstructive pulmonary disease (COPD). They improve lung functions in patients with COPD or reverse asthma symptoms. For the evaluation of lung functioning, pulmonary function tests are performed.
Bronchodilators are essential in diagnosing and treating lung conditions based on their effect on pulmonary function tests. The FEV1/FVC ratio compares the number of air flows during the first second of the exhalation (forced expiratory volume) to the theoretical amount of air an individual can push out in a maximum exhalation (forced vital capacity).
A typical ratio is 0.7. In reversible increased airway resistance like asthma, pre-bronchodilator pulmonary function tests will generally be less than 0.7. The ratio may be normalized after the administration of a short-acting bronchodilator. However, in nonreversible conditions like chronic obstructive pulmonary disease, giving a short-acting bronchodilator may not normalize the patient pulmonary function test levels.
Around 3.8 million Canadian age one or older were living with asthma in 2011-2012. Also, the number of Canadians living with the disease has risen between 2000-2001 and 2011-2012 due to the chronic nature of the disease. These rising cases of asthma and other lung diseases, coupled with the increasing awareness among the government, will surge the utilization of bronchodilators and thereby propel the market growth in the North America region.
The US market dominated the North America Bronchodilators Market by Country in 2021; thereby, achieving a market value of $8,928.6 million by 2028. The Canada market is experiencing a CAGR of 5.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 4.4% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
Bronchodilators are indicated for patients with lower than optimal airflow through the lungs. The central pillar of the treatment is beta-2 agonists, which target the smooth muscles of the lung’s bronchioles. Numerous respiratory conditions may need bronchodilators, including asthma and chronic obstructive pulmonary disease (COPD). They improve lung functions in patients with COPD or reverse asthma symptoms. For the evaluation of lung functioning, pulmonary function tests are performed.
Bronchodilators are essential in diagnosing and treating lung conditions based on their effect on pulmonary function tests. The FEV1/FVC ratio compares the number of air flows during the first second of the exhalation (forced expiratory volume) to the theoretical amount of air an individual can push out in a maximum exhalation (forced vital capacity).
A typical ratio is 0.7. In reversible increased airway resistance like asthma, pre-bronchodilator pulmonary function tests will generally be less than 0.7. The ratio may be normalized after the administration of a short-acting bronchodilator. However, in nonreversible conditions like chronic obstructive pulmonary disease, giving a short-acting bronchodilator may not normalize the patient pulmonary function test levels.
Around 3.8 million Canadian age one or older were living with asthma in 2011-2012. Also, the number of Canadians living with the disease has risen between 2000-2001 and 2011-2012 due to the chronic nature of the disease. These rising cases of asthma and other lung diseases, coupled with the increasing awareness among the government, will surge the utilization of bronchodilators and thereby propel the market growth in the North America region.
The US market dominated the North America Bronchodilators Market by Country in 2021; thereby, achieving a market value of $8,928.6 million by 2028. The Canada market is experiencing a CAGR of 5.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 4.4% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Beta-Adrenergic
- Xanthine Derivatives
- Anticholinergic
By Route of Administration
- Nasal (Inhalable)
- Oral
- Injectable
By Disease
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd
- Cipla Limited
- Viatris, Inc
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Bronchodilators Market, by Drug Class
1.4.2 North America Bronchodilators Market, by Route of Administration
1.4.3 North America Bronchodilators Market, by Disease
1.4.4 North America Bronchodilators Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Bronchodilators Market by Drug Class
3.1 North America Beta-Adrenergic Market by Country
3.2 North America Xanthine Derivatives Market by Country
3.3 North America Anticholinergic Market by Country
Chapter 4. North America Bronchodilators Market by Route of Administration
4.1 North America Nasal (Inhalable) Market by Country
4.2 North America Oral Market by Country
4.3 North America Injectable Market by Country
Chapter 5. North America Bronchodilators Market by Disease
5.1 North America Asthma Market by Country
5.2 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Bronchodilators Market by Country
6.1 US Bronchodilators Market
6.1.1 US Bronchodilators Market by Drug Class
6.1.2 US Bronchodilators Market by Route of Administration
6.1.3 US Bronchodilators Market by Disease
6.2 Canada Bronchodilators Market
6.2.1 Canada Bronchodilators Market by Drug Class
6.2.2 Canada Bronchodilators Market by Route of Administration
6.2.3 Canada Bronchodilators Market by Disease
6.3 Mexico Bronchodilators Market
6.3.1 Mexico Bronchodilators Market by Drug Class
6.3.2 Mexico Bronchodilators Market by Route of Administration
6.3.3 Mexico Bronchodilators Market by Disease
6.4 Rest of North America Bronchodilators Market
6.4.1 Rest of North America Bronchodilators Market by Drug Class
6.4.2 Rest of North America Bronchodilators Market by Route of Administration
6.4.3 Rest of North America Bronchodilators Market by Disease
Chapter 7. Company Profiles
7.1 Glenmark Pharmaceuticals Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.1.4 Recent strategies and developments:
7.1.4.1 Product Launches and Product Expansions:
7.2 Merck & Co., Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 GlaxoSmithKline PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 AstraZeneca PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Cipla Limited
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Viatris, Inc. (Mylan N.V.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.10. Sun Pharmaceutical Industries Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
Companies Mentioned
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Cipla Limited
- Viatris, Inc.
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
Methodology
LOADING...
